Regulation of RAN translation by PKR and eIF2A-P pathways
US11345911B2 · kind B2 · utility
5Cited by
12References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 17, 2018 |
| Grant date | May 31, 2022 |
| Priority date | — |
| Expiry date | Jan 15, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y207/01037
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods and compositions for modulating repeat non-ATG protein (RAN protein) translation are provided. In some aspects, the disclosure provides methods of inhibiting RAN protein translation by contacting a cell with an effective amount of an inhibitor of eIF2 phosphorylation or an inhibitor of protein kinase R (PKR). In some embodiments, methods described by the disclosure are useful for treating diseases associated with RAN protein translation, such as certain neurodegenerative diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.